Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy

Despite the prominent effects of BCR-ABL tyrosine kinase inhibitors (TKI) therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) and thus low incidence of blastic transformation, blast phase (BP)-CML remains a major therapeutic challenge in the TKI era. The “gatekeeper” mutation T3...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lu, Shi, Huiping, Shi, Wenyu, Yang, Li, Zhang, Yaping, Xu, Mengqi, Chen, Xiufang, Zhu, Yanv, Mu, Hui, Wan, Xiaochun, Yang, Zhonghua, Zeng, Ying, Liu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917542/
https://www.ncbi.nlm.nih.gov/pubmed/31997880
http://dx.doi.org/10.2147/OTT.S232102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917542/
https://www.ncbi.nlm.nih.gov/pubmed/31997880
http://dx.doi.org/10.2147/OTT.S232102

Ejemplares similares